Research progress of vericiguat in the treatment of chronic heart failure with reduced ejection fraction
-
摘要: 可溶性鸟苷酸环化酶(sGC)激动剂是一种新型的治疗心力衰竭的药物。它通过刺激sGC发挥作用，对心肌和血管功能有益处。维利西呱是首个被批准用于治疗成人有症状的慢性射血分数降低的心力衰竭(HFrEF)的口服sGC激动剂。该药耐受性良好，值得在临床中应用推广。现就其治疗慢性HFrEF的药理作用、疗效及耐受性等作一综述，以期为临床合理用药提供帮助。
-
关键词:
- 可溶性鸟苷酸环化酶激动剂 /
- 维利西呱 /
- 心力衰竭 /
- 射血分数降低
Abstract: Soluble guanylate cyclase(sGC) stimulators is a new drug in the treatment of heart failure. It works by stimulating sGC and is good for myocardial and vascular function. Vericiguat is the first oral sGC stimulator to be approved for the treatment of symptomatic chronic HFrEF in adults. The drug is well tolerated and is worth popularizing in clinical practice. This article reviews its pharmacological effects, efficacy and tolerance in the treatment of chronic HFrEF, in order to provide help for clinical rational drug use. -
-
[1] 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004
[2] 张班, 刘晓刚, 胡立群. 射血分数保留的心力衰竭研究新进展[J]. 临床心血管病杂志, 2022, 38(04): 271-275. https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2022.04.004
[3] 顾东风, 黄广勇, 何江, 等. 中国心力衰竭流行病学调查及其患病率[J]. 中华心血管病杂志, 2003, 31(1): 3-6. doi: 10.3760/j:issn:0253-3758.2003.01.002
[4] Roger VL. Epidemiology of heart failure: a contemporary perspective[J]. Circ res, 2021, 128(10): 1421-1434. doi: 10.1161/CIRCRESAHA.121.318172
[5] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36): 3599-3726. doi: 10.1093/eurheartj/ehab368
[6] Murphy SP, Ibrahim NE, Januzzi JL. Heart failure with reduced ejection fraction: a review[J]. Jama-Jam Med Assoc, 2020, 324(5): 488-504. doi: 10.1001/jama.2020.10262
[7] McDonald M, Virani S, Chan M, et al. CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction[J]. Can J Cardiol, 2021, 37(4): 531-546. doi: 10.1016/j.cjca.2021.01.017
[8] Butler J, Yang M, Manzi MA, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction[J]. J Am Coll Cardiol, 2019, 73(8): 935-944. doi: 10.1016/j.jacc.2018.11.049
[9] Zheng X, Zheng W, Xiong B, et al. The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis[J]. Medicine, 2018, 97(41): e12709. doi: 10.1097/MD.0000000000012709
[10] Hulot JS, Trochu JN, Donal E, et al. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options[J]. Expert Opin Pharmaco, 2021, 22(14): 1847-1855. doi: 10.1080/14656566.2021.1937121
[11] Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction[J]. N Engl J Med, 2020, 382(20): 1883-1893. doi: 10.1056/NEJMoa1915928
[12] 邓承豪, 陈康玉, 严激. 新型口服药物在慢性心力衰竭患者中的肾脏获益[J]. 临床心血管病杂志, 2021, 37(12): 1071-1074. doi: 10.13201/j.issn.1001-1439.2021.12.001
[13] Markham A, Duggan S. Vericiguat: first approval[J]. Drugs, 2021, 81(6): 721-726. doi: 10.1007/s40265-021-01496-z
[14] Armstrong PW, Roessig L, Patel MJ, et al. A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA Trial[J]. JACC-Heart Fail, 2018, 6(2): 96-104. doi: 10.1016/j.jchf.2017.08.013
[15] Gheorghiade M, Marti CN, Sabbah HN, et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure[J]. Heart Fail Rev, 2013, 18(2): 123-134. doi: 10.1007/s10741-012-9323-1
[16] Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED Randomized Trial[J]. J Am Med Assoc, 2015, 314(21): 2251-2262. doi: 10.1001/jama.2015.15734
[17] Kramer F, Voss S, Roessig L, et al. Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction[J]. Eur J Heart Fail, 2020, 22(9): 1675-1683. doi: 10.1002/ejhf.1787
[18] Ruehs H, Klein D, Frei M, et al. Population pharmacokinetics and pharmacodynamics of vericiguat in patients with heart failure and reduced ejection fraction[J]. Clin Pharmacokinet, 2021, 60(11): 1407-1421. doi: 10.1007/s40262-021-01024-y
[19] Boettcher M, Gerisch M, Lobmeyer M, et al. Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat, a soluble guanylate cyclase stimulator: results from preclinical and phase i healthy volunteer studies[J]. Clin Pharmacokinet, 2020, 59(11): 1407-1418. doi: 10.1007/s40262-020-00895-x
[20] Boettcher M, Loewen S, Gerrits M, et al. Pharmacodynamic and pharmacokinetic interaction profile of vericiguat: results from three randomized phase i studies in healthy volunteers[J]. Clin Pharmacokinet, 2021, 60(3): 337-351. doi: 10.1007/s40262-020-00935-6
[21] Boettcher M, Thomas D, Mueck W, et al. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects[J]. Eur J Clin Pharmacol, 2021, 77(4): 527-537. doi: 10.1007/s00228-020-03023-7
[22] Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. New Engl J Med, 2020, 382(20): 1883-1893. doi: 10.1056/NEJMoa1915928
[23] European Medicines Agency. Vericiguat(Verquvo)for heart failure[J]. Med Lett Drugs Ther, 2021, 63(1619): 36-37.
[24] Lam CSP, Giczewska A, Sliwa K, et al. Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA Trial[J]. JAMA Cardiol, 2021, 6(6): 706-712. doi: 10.1001/jamacardio.2020.6455
[25] Voors AA, Mulder H, Reyes E, et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA(Vericiguat Global Study in Subjects with HFrEF)trial[J]. Eur J Heart Fail, 2021, 23(8): 1313-1321. doi: 10.1002/ejhf.2221
[26] Ezekowitz JA, O'Connor CM, Troughton RW, et al. N-Terminal Pro-B-Type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study[J]. JACC-Heart Fail, 2020, 8(11): 931-939. doi: 10.1016/j.jchf.2020.08.008
[27] DeFilippi CR, Alemayehu W, Voors A, et al. Baseline cardiac troponin t, clinical outcomes and vericiguat treatment effect in heart failure with reduced ejection fraction study: insights from the victoria trial[J]. JACC, 2021, 18: 565.
[28] Ponikowski P, Alemayehu W, Oto A, et al. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial[J]. Eur J Heart Fail, 2021, 23(8): 1300-1312. doi: 10.1002/ejhf.2285
[29] Ezekowitz J. Changes in natriuretic peptide and effects of vericiguat in worsening heart failure with reduced ejection fraction: insights from VICTORIA(VerICiguaT Global Study in Subjects with HFrEF)[J]. Eur J Heart Fail, 2021, 23(Suppl S2): 2-322.
[30] Lam CSP, Mulder H, Lopatin Y, et al. Blood pressure and safety events with vericiguat in the VICTORIA Trial[J]. J Am Heart Assoc, 2021, 10(22): e021094. doi: 10.1161/JAHA.121.021094
[31] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. JACC, 2022, 79(17): e263-e421. doi: 10.1016/j.jacc.2021.12.012
[32] Butler J, Djatche LM, Lautsch D, et al. Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry[J]. J Card Fail, 2021, 27(12): 1374-1381. doi: 10.1016/j.cardfail.2021.06.019
[33] Mentz RJ, Mulder H, Mosterd A, et al. Clinical outcome predictions for the VerICiguaT global study in subjects with heart failure with reduced ejection fraction(VICTORIA)Trial[J]. J Card Fail, 2021, 27(9): 949-956. doi: 10.1016/j.cardfail.2021.05.016
[34] Aimo A, Pateras K, Stamatelopoulos K, et al. Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis[J]. Cardiovasc Drug Ther, 2021, 35(5): 1067-1076. doi: 10.1007/s10557-020-07099-2
[35] Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction[J]. JACC-Heart Fail, 2022, 10(2): 73-84. doi: 10.1016/j.jchf.2021.09.004
[36] Scalvini S, Bernocchi P, Villa S, et al. Treatment prescription, adherence, and persistence after the first hospitalization for heart failure: A population-based retrospective study on 100785 patients[J]. Int J Cardiol, 2021, 330(null): 106-111.
[37] Savarese G, Stolfo D, Sinagra G, et al. Heart failure with mid-range or mildly reduced ejection fraction[J]. Nat Rev Cardiol, 2022, 19(2): 100-116. doi: 10.1038/s41569-021-00605-5
[38] Alsumali A, Djatche LM, Briggs A, et al. Cost effectiveness of vericiguat for the treatment of chronic heart failure with reduced ejection fraction following a worsening heart failure event from a US medicare perspective[J]. Pharmacoeconomics, 2021, 39(11): 1343-1354. doi: 10.1007/s40273-021-01091-w
[39] Alsumali A, Lautsch D, Liu R, et al. Budget impact analysis of vericiguat for the treatment of chronic heart failure with reduced ejection fraction following a worsening event[J]. Adv Ther, 2021, 38(5): 2631-2643. doi: 10.1007/s12325-021-01681-2
-
计量
- 文章访问数: 1633
- PDF下载数: 1121
- 施引文献: 0
下载: